Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Receivables (2016 - 2025)

Arrowhead Pharmaceuticals (ARWR) has disclosed Receivables for 14 consecutive years, with $228.2 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Receivables rose 9027.24% year-over-year to $228.2 million, compared with a TTM value of $228.2 million through Dec 2025, up 9027.24%, and an annual FY2025 reading of $6.8 million, changed N/A over the prior year.
  • Receivables was $228.2 million for Q4 2025 at Arrowhead Pharmaceuticals, up from $6.8 million in the prior quarter.
  • Across five years, Receivables topped out at $228.2 million in Q4 2025 and bottomed at $150000.0 in Q4 2021.
  • Average Receivables over 5 years is $25.1 million, with a median of $2.4 million recorded in 2025.
  • The sharpest move saw Receivables crashed 98.47% in 2021, then skyrocketed 26278.67% in 2022.
  • Year by year, Receivables stood at $150000.0 in 2021, then surged by 26278.67% to $39.6 million in 2022, then plummeted by 96.85% to $1.2 million in 2023, then skyrocketed by 100.48% to $2.5 million in 2024, then skyrocketed by 9027.24% to $228.2 million in 2025.
  • Business Quant data shows Receivables for ARWR at $228.2 million in Q4 2025, $6.8 million in Q3 2025, and $9.7 million in Q2 2025.